The World Health Organization has come out with the first ever guidelines on the global use of Glucagon-Like Peptide-1 (GLP-1) medicines for “treating obesity as a chronic, relapsing disease.”
The WHO, in a blog post published on 1 December, notes…
WHO calls obesity a chronic disease, endorses GLP-1 drugs with behavioural therapy in fresh guidelines
